AJMC November 13, 2024
Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.
Early in a biosimilar’s life cycle, it can be challenging to gain a foothold, but over time biosimilars are gaining traction and becoming preferred products, said James D. Chambers, PhD, professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.
This transcript has been lightly edited for clarity.
Transcript
Considering safety and efficacy is the same, but the cost is cheaper, why wouldn’t a payer prefer a biosimilar over the originator product on formulary?
I think, historically, there’s been some reticence about biosimilars and, are they...
Today's Sponsors
Today's Sponsor